Loss of maspin expression in prostate cancer induced by a P53- and HER-2- pathway/overexpression profiling by whole-mount derived tissue microarrays

By Merseburger A.   Kuczyk M.   David M.   Moul J.   Sesterhenn I.   Jonas U.   Mostofi F.   Srivaslava S.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 61-61

Elsevier

Access to resources Recommend Favorite

p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy

By Huang A.   Gandour-Edwards R.   Rosenthal S.A.   Siders D.B.   Deitch A.D.   Devere White R.W.  

Urology, Vol. 51, Iss. 2, 1998-02 ,pp. : 346-351

Elsevier

Access to resources Recommend Favorite

Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression

By Abdelzaher Eman  

British Journal of Neurosurgery, Vol. 25, Iss. 6, 2011-12 ,pp. : 707-713

Informa Healthcare

Access to resources Recommend Favorite

p53, bcl-2, and Bax Expression in Renal Cell Carcinoma - immunohistochemical detection of p53 protein versus clinicopathologic parameters

By Vasavada S.P.   Novick A.C.   Williams B.R.G.  

Urology, Vol. 51, Iss. 6, 1998-06 ,pp. : 1057-1061

Elsevier

Access to resources Recommend Favorite

Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer

By Linjawi A.   Kontogiannea M.   Halwani F.   Edwardes M.   Meterissian S.  

Journal of the American College of Surgeons, Vol. 198, Iss. 1, 2004-01 ,pp. : 83-90

Elsevier

Access to resources Recommend Favorite